Continue with FacebookLooking to list your PhD opportunities? Log in here.
trials PhD Projects, Programmes & Scholarships
We have 243 trials PhD Projects, Programmes & Scholarships
PhD saved successfully
Changing behaviour to enable design and delivery of low carbon trials
Fifteen years ago, the Sustainable Trials Study Group concluded that ‘clinical trials contribute to greenhouse gas emissions.’ and current estimates predict that the 350,000 trials registered on clinicaltrials.gov have a carbon usage of 27.5M tonnes. Read more
Modelling multiple ordinal outcomes in clinical trials
Ordinal outcome data are frequently reported in clinical trials, where participants’ outcomes are “rated” on ordered categorical scales. Read more
Developing methodology for antibiotic stewardship trials in critical care
Critically ill patients have high mortality, morbidity, and healthcare resource use. Up to 70% of patients in critical care receive antibiotics. Read more
Methods to account for delay in registration of outcomes in trials
Some clinical trials use active follow-up of participants to obtain data on outcomes. For example, data on safety and efficacy outcomes might be obtained during follow-up appointments with a research nurse. Read more
Continuous-time models for the analysis of cluster randomised trials
Cluster randomised trials are a widely used method of evaluating interventions applied to groups of people, like schools or villages, or when the outcomes of people within these groups are correlated with one another. Read more
Getting the questions right: Developing guidance and exemplars for a multi-stakeholder approach to estimands in cancer clinical trials
Estimands are used in clinical trials to ensure that we are asking (and answering) the right research questions. The estimand framework provides a structured approach for explicit specification of what we plan to estimate in order to address the questions that are important to different stakeholders(1). Read more
ELICITING EXPERT KNOWLEDGE IN THE DESIGN AND ANALYSIS OF TRIALS IN RARE DISEASES
There are more than 7000 diseases with low incidence rates (rare diseases), of which 75% affect children, and 30% of rare disease patients die before they reach 5 years old. Read more
Remote delivery of complex interventions within trials: understanding and applying knowledge from COVID-19 adaptations to guide future delivery, inclusivity and tailoring of trial interventions
The COVID-19 pandemic had a major impact on many aspects of the design and delivery of clinical trials, leading to rapid adaptations to enable trials to continue to operate in an unfamiliar and challenging environment. Read more
Improving the Design of Vector Control Trials
Vector-borne Diseases (VBDs) are a major source of global morbidity and mortality. Interventions for many VBDs are based on control of mosquito populations. Read more
On the value of randomisation in designing small population clinical trials
Phase II trial designs, conventionally in a homogeneous patient population, can be subdivided into two distinct types. i) single-arm (non-randomised) designs comparing the efficacy against historical controls, ii) randomised designs with a contemporary control arm. Read more
Enhancing the transparency and communication of the results of randomised trials to research participants and the public (NDORMS 2023/6)
Randomised controlled trials provide the best evidence about the benefits and harms of health care interventions and are a crucially important part of the practice of evidence-based healthcare. Read more
Agile development methodology of matched synthetic control for Bayesian trials in the era of genomics medicine
Integrative analysis of wealth of biological and clinical data generated from clinical trials allow us to fully delineate these tumours to prognostic and predictive biomarkers for treatment response. Read more
Issues in cost–effectiveness analysis for multinational clinical trials
The multinational trial has seen an increase in its popularity. Read more
A methodological framework for incorporating multiple outcomes into hybrid implementation and effectiveness trials
Many policies are adopted into practice without a solid evidence. Rigorous randomised trials are therefore needed to inform decisions about the implementation of policy interventions. Read more
Design and analysis of early phase adaptive platform trials in the era of precision oncology
We need efficient, innovative and robust early phase I/II trial designs to swiftly test new cancer therapies and ensure safe and effective ones are being progressed to later stage trials. Read more